ReviewDie Ophthalmologie2026
[Extracellular vesicles and their potential in ophthalmology].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracellular vesicles (EV), especially small EV and microvesicles, are considered promising biomarkers as they transport molecular information from their tissue of origin and can thus reflect pathological processes. They are increasingly being investigated as biomarkers in ocular diseases.
objectiveThe aim of this study was to present the current state of knowledge on the role of EV as biomarkers for ocular diseases, to compare sample sources and to discuss the associated methodological challenges as well as clinical perspectives. MATERIAL AND
methodsThis work is based on a literature search of current original articles and reviews, complemented by tabular overviews of identified EV-associated markers for ocular diseases.
resultsThe potential of EV as biomarkers for ocular diseases is currently being studied in tears, aqueous humor, vitreous humor, blood and urine. Alterations in EV concentration and size as well as disease-specific signatures have been reported. Numerous EV-associated molecules, particularly microRNA (miRNA) and proteins, have been proposed for diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, myopia and ocular tumors.
conclusionAlthough EV hold great promise as diagnostic and prognostic tools in ophthalmology, validated markers and standardized isolation and detection methods are still lacking. Key challenges include lipoprotein contamination, limited sample volumes and interindividual variability (e.g. age, sex, fasting status). In the future, after overcoming these technical challenges, small EV and microvesicles could serve as liquid biopsy tools for screening, disease monitoring and personalized management of ocular diseases.
Indexed as
Identifiers
41661268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.